Veeva Systems Inc. Advances Infant Nutrition with Glycoprotein Formula Study

Veeva Systems Inc ((VEEV)) announced an update on their ongoing clinical study.

Study Overview: The clinical study titled ‘Feeding Tolerance and Gut Maturation of Infants Consuming a Formula Rich in Glycoprotein’ aims to evaluate the effectiveness of a glycoprotein-rich infant formula on gastrointestinal tolerance and health in healthy term infants. This study is significant as it seeks to compare the effects of formula feeding to breastfeeding, focusing on gut health and development.

Intervention/Treatment: The intervention being tested is a commercially available starter infant formula, enriched with glycoproteins, designed to support gut health and maturation in infants. The formula is intended to mimic the benefits of breast milk.

Study Design: This is a non-randomized, single-arm, open-label study with a parallel group design. It involves two groups: one receiving the formula and a reference group of breastfed infants. The study’s primary purpose is observational, with no masking involved.

Study Timeline: The study began on July 9, 2021, and was completed with the last update submitted on June 30, 2025. These dates are crucial as they mark the study’s progression and completion, providing a timeline for data analysis and results dissemination.

Market Implications: The completion of this study could impact Veeva Systems Inc.’s stock performance positively, as it highlights their involvement in innovative nutritional research. The results could influence investor sentiment, particularly if the formula demonstrates comparable benefits to breastfeeding. Competitors in the infant nutrition industry may also be affected as the study’s findings could shift market dynamics.

The study is completed, and further details are available on the ClinicalTrials portal.